Biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases through cutting-edge science and medicine.
Founded in 1978, Biogen is a pioneer in biotechnology, and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics.
With approximately 7000 people worldwide, we are truly a global organization headquartered in Cambridge, Massachusetts, also home to our research operations. Our international headquarters are based in Zug, Switzerland, and we have world-class manufacturing facilities in North Carolina and Denmark. We offer therapies globally through a direct affiliate presence in 30 countries and a network of distribution partners in over 50 additional countries.